^Preclinical data support future clinical development of AWK,
that target Claudin-6 and NaPi2b
Additional presentations include clinical and independent preclinical studies
to evaluate ADCT-601 targeting AXL
LAUSANNE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) — ADC Therapeutics SA (NYSE:
ADCT) today announced that abstracts on its novel antibody
Drug conjugates (ADCs) for presentation at the annual meeting of the American
Association for Cancer Research (AACR) which took place from 5th to 10th.
April 2024 in San Diego, California.
“We are pleased to report compelling preclinical data at the AACR Annual Meeting
to be able to present the future clinical development of the AWK in the next
generation in our solid tumor portfolio, including
those targeting Claudin-6 and NaPi2b,” said Dr. Mohamed Zaki, Chief
Medical Officer of ADC Therapeutics.?We also look forward to the results
independent studies demonstrating the potential of another ADC, ADCT-601, targeting AXL
aims to highlight.”
Details of ADC Therapeutics’ poster presentations can be found in the
following:
Title: Preclinical development of a novel camptothecin-based antibody drug
conjugate targeting solid tumors expressing Claudin-6 (Preclinical development
a novel antibody-drug conjugate based on camptothecin
solid tumors that express claudin-6)
Abstract: 3122
Session title: Antibody-Drug Conjugates
Date and time: Monday, April 8, 2024; 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 21; Board number 3
Title: Preclinical development of NaPi2b-PL2202, a novel camptothecin-based
antibody-drug conjugate targeting solid tumors expressing NaPi2b (Preclinical
Development of NaPi2b-PL2202, a novel antibody-drug conjugate
camptothecin-based against solid tumors expressing NaPi2b)
Abstract: 5085
Session title: Novel Immunotherapies and Immune Modulation
immunotherapies and immune modulation)
Date and time: Tuesday, April 9, 2024; 9:00 a.m. – 12:30 p.m. PT
Location: Poster Section 42; Plate number 7
Title: Phase 1b Trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in
patients with advanced bone and soft tissue sarcomas (Phase Ib study on
Dose Escalation of Mipasetamab Uzoptirine (ADCT-601-102) in Patients With
advanced bone and soft tissue sarcomas)
Abstract: CT059
Session Title: Phase I Clinical Trials 1
Date and time: Monday, April 8, 2024; 9:00 a.m. – 12:30 p.m. PT
Location: Poster section 48; Plate number 9
Title: Quantitative systems pharmacology modeling of loncastuximab tesirine
combined with mosunetuzumab and glofitamab helps guide dosing for patients with
DLBCL (Quantitative systems pharmacological modeling of loncastuximab-
Tesirine in combination with mosunetuzumab and glofitamab helps with dosage
for patients with DLBCL)
Abstract: 875
Session title: Application of Bioinformatics to Cancer Biology 1 (Application of the
Bioinformatics on cancer biology 1)
Date and time: Sunday, April 7, 2024; 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 36; Plate number 19
Details of an independent poster presentation of a preclinical study
for ADCT-601 can be found below:
Title: Preclinical anti-tumorigenic evaluation of AXL targeting antibody-drug-
conjugate in an adenoid cystic carcinoma cell line xenograft model (Preclinical
antitumor evaluation of an antibody drug directed against AXL
conjugate in a xenotransplantation model for adenoid cystic carcinoma)
Abstract: LB022
Session Title: Late-Breaking Research: Chemistry
Date and time: Sunday, April 7, 2024; 1:30 p.m. – 5:00 p.m. PT
Location: Poster Section 52; Board number 4
Details of an NCI-led ADCT-701 oral presentation
Study can be found below:
Title: Targeting DLK1, a Notch ligand, with an antibody-drug conjugate in
adrenocortical carcinoma (targeting DLK1, a Notch ligand, with a
Antibody-drug conjugate for adrenocortical carcinoma)
Abstract: 6573
Session Type: Minisymposium
Session title: Molecular, Preclinical, and Clinical Endocrinology 3
preclinical and clinical endocrinology 3)
Date and time: Tuesday, April 9, 2024; 3:05 p.m. – 3:20 p.m. PT
Place will be announced
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a global leader in commercial
Stage-active company and pioneer in the field of antibody drug development
Conjugates (AWK). The company is developing its proprietary AWK technology
further to develop the treatment paradigm for patients with hematological malignancies
and solid tumors.
ADC’s CD19-targeting ADC ZYNLONTA (loncastuximab-tesirine-lpyl).
Therapeutics received accelerated approval from the FDA and the
European Commission granted conditional approval for the treatment of the
relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also located in the
Development in combination with other active ingredients and in earlier
lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has several AWKs in the
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland
through offices in London, the San Francisco Bay Area and New Jersey. For
For more information please visit https://adctherapeutics.com/ and follow
You can follow the company on LinkedIn (https://www.linkedin.com/company/adc-
therapeutics/).
ZYNLONTA(®) is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Safe-
Harbor provisions of the Private Securities Litigation Reform Act of 1995. In
In some cases, you can identify forward-looking statements by terms such as “may”,
“will”, “should”, “would”, “expect”, “intend”, “plan”,
“anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”,
“aim”, “future”, “continue” or “appear” or negation
of these terms or similar expressions, although not all
forward-looking statements contain these identifying words.
Forward-looking statements are subject to certain risks and uncertainties,
which could cause actual results to differ materially
differ as described. Among the factors that cause such differences
can include, among other things: the future success and results of the
various ADCT development programs presented at the AACR Annual Meeting
were presented, the actual sales of ZYNLONTA(®) for the 4th quarter
2023, the success of the company’s updated corporate strategy,
including operational efficiency, capital utilization and the
prioritizing the portfolio; the company’s ability to withstand the decline
To achieve the expected total cost of ownership for 2023 and 2024
Liquidity reserve until the 4th quarter of 2025, the effectiveness of the new
commercial market launch strategy, competition through new technologies
and the Company’s ability to increase sales of ZYNLONTA(®).
United States; the ability of the Swedish Orphan Biovitrum
AB (Sobi(®)), ZYNLONTA(®) successfully in the European Economic Area
market, as well as market acceptance, appropriate cost reimbursement and
future revenue from this product; the approval of Overland ADCT
BioPharma’s BLA for ZYNLONTA(®) in China through the NMPA and future
Revenue from it, the ability of our strategic partners, including
Mitsubishi Tanabe Pharma Corporation, the regulatory approval for
ZYNLONTA(®) in foreign jurisdictions and the timing
and the amount of future income and payments to us from such
partnerships; the possible impact of the University of Miami on her
IIT in FL reported data; the schedule and results of the clinical
Studies conducted by the Company or its partners, including LOTIS 5 and 7, ADCT
601 and 602 as well as the company’s early-stage research projects
Pipeline; Actions taken by the FDA or foreign regulatory authorities regarding
the Company’s products or product candidates; projected revenue
and expenses; the company’s debt, including healthcare
Royalty Management and Oaktree and Blue Owl facilities, and the
Restrictions on the company’s business activities caused by these
Debt imposed, the ability to repay that debt
and the significant cash available to service that debt
required are; and the company’s ability, financial and other
resources for its research, development, clinical and commercial activities
to receive activities. For more information on these and other factors,
which could cause actual results to differ materially from those stated in
Expected differences from the forward-looking statements can be found in the section
“Risk Factors” in the Company’s Annual Report on Form 20-F and in the
the Company’s other periodic reports and filings with the
Securities and Exchange Commission. These statements are with well-known and
unknown risks, uncertainties and other factors that may arise
may result in actual results, performance, achievements or
future results, performance, successes or prospects
Outlook may differ from those expressed in such forward-looking statements
were brought or implied. The company warns investors to be careful
rely on the forward-looking statements contained in this document.
The Company undertakes no obligation to accept these forward-looking statements
revise or update to reflect events or circumstances after
The date of this press release will be adjusted unless otherwise required by law
is prescribed.
CONTACTS:
Investors and media
Nicole Riley
ADC Therapeutics
[email protected] (mailto:[email protected])
+1 862-926-9040
°